MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/vaccines8020289

Медицинская библиотека · Vaccines · 2020

Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.

Lage Daniela P, Ribeiro Patrícia A F, Dias Daniel S, Mendonça Débora V C, Ramos Fernanda F, Carvalho Lívia M, Steiner Bethina T, Tavares Grasiele S V, Martins Vívian T, Machado Amanda S, Oliveira-da-Silva João A, Santos Thaís T O, Freitas Camila S, Oliveira Jamil S, Roatt Bruno M, Machado-de-Ávila Ricardo A, Humbert Maria V, Christodoulides Myron, Coelho Eduardo A F

СтатьяПеревод пока не подготовлен

Аннотация

Background

Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation.

Methods

BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo.

Results

Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels.

Conclusions

Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL.

Для цитирования: Lage Daniela P, Ribeiro Patrícia A F, Dias Daniel S, Mendonça Débora V C, Ramos Fernanda F, Carvalho Lívia M, Steiner Bethina T, Tavares Grasiele S V, Martins Vívian T, Machado Amanda S, Oliveira-da-Silva João A, Santos Thaís T O, Freitas Camila S, Oliveira Jamil S, Roatt Bruno M, Machado-de-Ávila Ricardo A, Humbert Maria V, Christodoulides Myron, Coelho Eduardo A F. Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.. Vaccines. 2020. DOI: 10.3390/vaccines8020289.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.